Open AccessEfficacy and safety of using the dipeptidylpeptidase-4 inhibitor in patients with type 2 diabetes mellitus and early stages of diabetic nephropathy
Author(s) -
V. I. Pankiv,
H. Yu. Kozlovska
Publication year - 2013
Publication title -
bukovinsʹkij medičnij vìsnik
Language(s) - English
Resource type - Journals
eISSN - 2413-0737
pISSN - 1684-7903
DOI - 10.24061/2413-0737.xvii.1.65.2013.19
Subject(s) - saxagliptin , medicine , metformin , glycated hemoglobin , diabetic nephropathy , diabetes mellitus , hypoglycemia , type 2 diabetes mellitus , endocrinology , type 2 diabetes , nephropathy , gastroenterology , sitagliptin
The research analyzes the effect of differentiated antihyperglycemic therapy on the carbohydrate parameters and kidney functional state in patients with type 2 diabetes mellitus (DM) with early stages of diabetic nephropathy. It has been established that the preseripton of saxagliptin in combination with metformin resulted in a reliable reduction of glycated hemoglobin, the attainment of target blood glucose levels. At the same time patients during the period of treatment had no episodes of hypoglycemia, the body weight did not increase. The absence of a negative influence of saxagliptin in combination with metformin treatment on the indices of the kidney functional state in patients with type 2 DM with early stages of diabetic nephropathy has been marked.